EU: More Inspections and GMP Non-Compliance Statements

Recommendation
28/29 October 2025
Hamburg, Germany
A CAPA Workshop on Successful Failure Investigation
The EU GMP inspectorates inspected more drug manufacturing facilities in 2017, according to the 2017 Annual Report from the European Medicines Agency (EMA). Also more inspections are now performed in the EU. Last year 2.122 inspections were conducted by EEA authorities in the EU/EEA (1.956 in 2016) and seven GMP Non-Compliance Statements were issued (five in 2016). Altogether, 2.493 inspections were performed worldwide (2.293 in 2016) leading to 17 GMP Non-Compliance Statements.
On the other hand, according the report, "the number of GMP inspections requests within the context of centralised marketing procedure declined in 2017". This decrease also reflects the implementation of the EU-US MRA. With this agreement, the equivalence of supervisory standards are recognised, inspection reports of the FDA can be accepted and inspections on each other's territories are reduced.
Source: European Medicines Agency Annual Report 2017.
Related GMP News
22.10.2025EMA Questions & Answers on Mutual Recognition Agreement (MRA) with US updated
22.10.2025FDA continues to take Root Cause Analysis and CAPA very seriously
14.10.2025Two new GDP Non-Compliance Reports from Romania
01.10.2025Alternative Inspection Methods of the FDA
24.09.2025FDA issues final Guidance on Remote Oversight Tools
24.09.2025Four Warning Letter concerning CAPA and Root Cause Analysis published


